目的 探讨肿瘤转移相关蛋白3（MTA3）与乳腺癌预后的相关性。方法 选择160例乳腺癌病例制成的组织芯片，带有表皮生长因子受体（EGFR）数据、雌激素受体（ER）数据和随访信息，采用免疫组织化学方法检测MTA3蛋白的表达，分析其与预后的相关性。结果 在EGFR+/ER-乳腺癌中，癌组织MTA3表达高的患者有更长的总生存期(67.9%与41.2%，P=0.059)；在EGFR-/ER+乳腺癌中，癌组织MTA3表达低的患者有更长的总生存期（100.0%与72.0%，P=0.039）；在EGFR+/ER+乳腺癌组中，癌组织MTA3表达与患者预后无关（P=0.405）。结论 MTA3在乳腺癌中的功能可能受EGFR信号网络和ER信号网络的双向调控，最终影响患者预后。

Objective To investigate the correlation between metastasis-associated protein 3 (MTA3) and the prognosis of patients with breast cancer. Methods Tissue microarrays were made using 160 breast cancer samples and contained epidermal growth factor receptor (EGFR) data, estrogen receptor (ER) data, and follow-up information. The expression of MTA3 protein was detected by immunohistochemical method and the correlation between the expression of MTA3 and the prognosis was analyzed. Results For EGFR+/ER- breast cancer, the overall survival of patients with high expression of MTA3 in cancer tissues was longer (67.9% and 41.2%, P=0.059). For EGFR-/ER+ breast cancer, the overall survival of patients with low expression of MTA3 in cancer tissues was longer (100.0% and 72.0%, P=0.039). For EGFR+/ER+ breast cancer, the expression of MTA3 in cancer tissues did not correlate to the prognosis (P=0.405). Conclusion The function of MTA3 may be bi-directionally regulated by EGFR and ER pathways, so as to affect the prognosis of patients with breast cancer.